Replimune Group, Inc. (REPL)

3.30 -0.14 (-4.07%) USD  |  NASDAQ  |  May 07, 12:17
More

Replimune Group SG&A Expense (TTM) : 103.07M for Dec. 31, 2025

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for REPL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
ANI Pharmaceuticals, Inc. 317.74M
Bristol Myers Squibb Co. 7.30B
Phathom Pharmaceuticals, Inc. 239.25M
REGENXBIO, Inc. 82.86M
Catalyst Pharmaceuticals, Inc. 171.18M